Position in IMNM
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$18,203,820
+$16,982,228 QoQ
Shares Held
859,076
+1438.0% QoQ
Ownership
0.756%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#25
of 202 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 92%
Shared 0%
None 8%
Common Shares in IMNM Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MetLife Investment Management, LLC holds $430,307,229 across 249 Biotechnology names. IMNM ranks #6 (4.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
402,605 | $31,511,893 | |
| 2 | PRAX |
Praxis Precision Medicines, Inc.
|
90,543 | $30,312,890 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
58,072 | $28,846,104 | |
| 4 | FTRE |
Fortrea Holdings Inc.
|
1,362,169 | $23,701,740 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
89,662 | $21,946,567 | |
| 6 | IMNM |
Immunome Inc.
This page
|
859,076 | $18,203,820 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22,880 | $14,266,595 | |
| 8 | CYTK |
Cytokinetics Inc
|
140,046 | $11,930,518 |
All Filings in IMNM
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $18,203,820 | 859,076 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $1,221,592 | 55,857 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $1,117,690 | 52,034 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $496,632 | 42,411 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $394,422 | 42,411 | Shares | Defined | 2025-08-13 | |
| 2025-03-31 | $285,426 | 42,411 | Shares | Defined | 2025-05-14 | |
| 2024-12-31 | $378,273 | 35,619 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $442,474 | 30,265 | Shares | Defined | 2024-11-13 | |
| 2024-06-30 | $159,865 | 13,212 | Shares | Defined | 2024-08-13 | |
| No filing history on record for this holder in this stock. | ||||||